Russel Metals (TSX: RUS) completes acquisition of seven Kloeckner service centers
Russel Metals completes $102M Kloeckner acquisition, expanding in the U.S. South and Midwest. Find out how this shapes its strategy and market position.
Why Capstone Copper’s latest mine dispute could ripple through Chile’s copper sector
Capstone Copper miners strike at Mantoverde after failed negotiations. Find out what it means for production, strategy, and copper market risk in 2026.
Photronics (PLAB) announces CTO transition as Christopher Progler prepares exit in FY2026
Photronics announces CTO transition as Christopher Progler steps down. Find out what this means for its semiconductor strategy, R&D focus, and industry position.
Can First Solar’s capital playbook help SanDisk navigate memory market headwinds?
SanDisk adds First Solar CFO Alexander Bradley to its board. Find out what this move signals for SanDisk’s capital strategy and flash business future.
Coast Copper (TSXV: COCO) CEO Adam Travis raises stake to 19.42% as insiders tighten control
Coast Copper CEO Adam Travis raises stake to 19.42%, signaling confidence ahead of 2026 drilling. Find out what this means for the company and investors.
Bausch + Lomb completes credit agreement amendment, reducing interest cost on $2.8bn debt
Find out how Bausch + Lomb’s $2.8B refinancing plan reshapes its debt profile, reduces interest margins, and defers amortization until 2026.
MKDWELL Tech goes private with $7m share repurchase — here’s what it means
MKDWELL Tech announces a $7 million share buyback through private agreements. Explore what this means for valuation, capital strategy, and investor sentiment.
Can Riot Platforms’ new CFO turn Bitcoin volatility into infrastructure value in 2026?
Riot Platforms names Jason Chung as CFO amid a shift to infrastructure-led growth. Find out what this transition means for capital strategy and 2026 execution.
What’s driving GH Research’s stock spike? FDA IND verdict looms for lead depression candidate
GH Research is set to update investors on its FDA IND filing and Phase 3 launch plans for GH001. Find out what this means for its future in depression treatment.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.